Combining influenza and COVID-19 vaccination (ComFluCOV) study

Phase 4

Completed

• Conditions: Adults receiving the influenza (flu) vaccine who may also need COVID-19 booster vaccines; Infections and Infestations; COVID-19 (SARS-CoV-2 infection)

• Registration Number: ISRCTN14391248
• Lead Sponsor: niversity Hospitals Bristol NHS Foundation Trust

Brief Summary

2021 Results article in https://pubmed.ncbi.nlm.nih.gov/34774197/ (added 15/11/2021) Other publications see attached file ISRCTN14391248_participant results_v1.0_01October2021.pdf [1.0] Summary of results for participants (added 17/03/2023) 2024 Other publications in https://pubmed.ncbi.nlm.nih.gov/38212836/ implementation (added 12/01/2024) 2024 Other publications in https://pubmed.ncbi.nlm.nih.gov/38263245/ statistical methodologies implementation (added 24/01/2024)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-03-30
• Study Completion: 2023-02-21
• Last Update Posted: 5 February 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 679

Inclusion Criteria

1. Aged =18 years
2. Received one dose of either:
2.1. ChAdOx1 vaccine, 56 to 90 days prior to trial enrolment
2.2. BNT162b2 vaccine, 28 and 90 days prior to trial enrolment
3. Agree to refrain from blood donation in the 7 days following vaccination (at both visits 1 and 2)
4. Willing to allow their General Practitioner (GP) and consultant, if appropriate, to be notified of participation in the trial
5. Willing to allow investigators to discuss their medical history and confirm vaccination status with their GP, and access all medical records when relevant to trial procedures
6. Willing and able to give written informed consent for participation in the trial
7. Able to use and has access to an electronic device (such as a laptop, tablet, or smartphone) to complete trial procedures (such as the e-diary)
8. Able and willing to comply with all trial requirements, in the Investigator’s opinion

Exclusion Criteria

Current exclusion criteria as of 07/05/2021:
1. Receipt of any vaccine (licensed or investigational) other than ChAdOx1 or BNT162b2 within 30 days before visit 1
2. Administration of immunoglobulins and/or any blood products within three months before visit 1
3. History of allergic disease or reactions likely to be exacerbated by any component of trial vaccines (for example hypersensitivity to the active substance or any of the SmPC-listed ingredients)
4. Bleeding disorder (e.g., factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following intramuscular injections or venepuncture and any history of cerebral venous sinus thrombosis, acquired or hereditary thrombophilia, heparin-induced thrombocytopenia or antiphospholipid syndrome. Those who have experienced major venous and arterial thrombosis occurring with thrombocytopenia following vaccination with any COVID-19 vaccine should not receive a second dose of COVID-19 Vaccine AstraZeneca.
5. Continuous use of anticoagulants, such as coumarins and related anticoagulants (such as warfarin) or novel oral anticoagulants (such as apixaban, rivaroxaban, dabigatran, and edoxaban)
6. Suspected or known current alcohol or drug dependency
7. Any other significant disease, disorder, or finding which may significantly increase the risk to the participant, affect their ability to participate in the trial, or impair interpretation of the trial data
8. Current, active, and progressive neurological disorders (such as multiple sclerosis, Guillain-Barre syndrome, transverse myelitis). Bell’s palsy will not be an exclusion criterion
9. Scheduled elective surgery during trial participation if this interferes with the study protocol
10. Participated in another research trial involving an investigational product in the 12 weeks prior to visit 1, or if receipt of any IMP is planned during the trial period
11. Acute, ongoing respiratory illness (moderate or severe illness, with or without fever) at visit 1
12. Fever (oral temperature >37.8°C) at visit 1

Previous exclusion criteria:
1. Receipt of any vaccine (licensed or investigational) other than ChAdOx1 or BNT162b2 within 30 days before visit 1
2. Administration of immunoglobulins and/or any blood products within three months before visit 1
3. History of allergic disease or reactions likely to be exacerbated by any component of trial vaccines (for example hypersensitivity to the active substance or any of the SmPC-listed ingredients)
4. Bleeding disorder (for example factor deficiency, coagulopathy, or platelet disorder), or prior history of significant bleeding or bruising following intramuscular injections or venepuncture
5. Continuous use of anticoagulants, such as coumarins and related anticoagulants (such as warfarin) or novel oral anticoagulants (such as apixaban, rivaroxaban, dabigatran, and edoxaban)
6. Suspected or known current alcohol or drug dependency
7. Any other significant disease, disorder, or finding which may significantly increase the risk to the participant, affect their ability to participate in the trial, or impair interpretation of the trial data
8. Current, active, and progressive neurological disorders (such as multiple sclerosis, Guillain-Barre syndrome, transverse myelitis). Bell’s palsy will not be an exclusion criterion.
9. Scheduled elective surgery during trial participation if this interferes with the study protocol
10. Participated in another research trial involving a

Study & Design

• Study Type: Interventional
• Study Design: Not specified